European Pharmaceutical Review

OCTOBER 19, 2023

we must prove the effectiveness of radiopharmaceuticals through clinical trials… This has been demonstrated recently with PLUVICTO… the first US Food and Drug Administration (FDA)-approved targeted radioligand therapy for eligible patients with prostate cancer” At this moment, there is no single treatment for cancer today.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Side effects Doctors 105

Pharmaceutical Technology

JULY 29, 2022

Janssen’s Risperdal (risperidone), a second-generation antipsychotic , got its first FDA approval for autism-related irritability for children over the age of five, in 2006. Generic versions of both drugs are now available. The route of administration is another hurdle as both drugs come in the forms of oral pills or injections.

Side effects 105

Side effects Medical Pharmaceutical Management 105

pharmaphorum

NOVEMBER 4, 2022

Galapagos is in the roll-out phase for its first commercial products – JAK1 inhibitor Jyseleca (filgotinib) for rheumatoid arthritis – which has been approved in Europe and Japan but fell foul of FDA concerns about the class’s safety and was rejected in the US.

Side effects 52

Side effects Safety FDA Sales 52

Medgadget

MAY 2, 2023

These treatments at times come with a long list of side effects, leaving many patients in search of an effective long-term solution. For some patients with PTSD, psychotherapy may not be an effective option, they may find talking about their traumatic experience stress inducing, untherapeutic or ineffective.

Side effects 86

Side effects Prescription Healthcare Healthcare 86

Pharmaceutical Technology

NOVEMBER 29, 2022

In 1970, the FDA approved ketamine as an anesthetic. In March 2019, the American regulator approved esketamine , an enantiomer of ketamine, for use in treatment-resistant depression as a nasal spray. Generally, side effects are present in high doses, he explains. The drug is also known for its illegal recreational use.

Side effects 110

Side effects Pharmaceutical Patients Medicine 110

Pharmaceutical Technology

FEBRUARY 13, 2023

At the same time, continuing research into seizures remains key as many available options have side effects and do not benefit all patients. In November 2019, SK Life Science’s Xcopri (cenobamate) was approved for partial-onset seizures in adults. SK Life Science is a subsidiary of SK, a South Korean holding company.

Patients 105

Patients Side effects Medical Engineering 105

European Pharmaceutical Review

SEPTEMBER 22, 2023

Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.

Food and Drug Administration 97

Food and Drug Administration Safety Patients Leads 97

Pharmaceutical Technology

OCTOBER 10, 2022

The company plans to submit a request for advice from the FDA at the end of this year or the start of 2023, he adds. In 2015, the FDA approved Sprout Pharmaceuticals’s Addyi, also known under the generic name flibanserin, for use by pre-menopausal women with hypoactive sexual desire disorder (HSDD).

Pharmacology 59

Pharmacology Side effects FDA Safety 59

pharmaphorum

DECEMBER 15, 2022

Back in 2015, the influencer-of-influencers, Kim Kardashian, was slammed for failing to mention the potential side effects of an anti-nausea drug, leading to the US FDA getting involved. Despite the slap on the wrist, the campaign was highly effective and there is no sign of this approach going away.

Media 84

Media Healthcare Healthcare Education 84

Impetus Digital

JANUARY 3, 2023

Back in 2015, the influencer-of-influencers, Kim Kardashian, was slammed for failing to mention the potential side effects of an anti-nausea drug, leading to the US FDA getting involved. Despite the slap on the wrist, the campaign was highly effective and there is no sign of this approach going away.

Media 52

Media Healthcare Healthcare Recruitment 52

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. The Health Survey for England 2019 reported that 28% of adults in the UK were obese and 36.2% The drug was approved to treat type 2 diabetes mellitus in May. were overweight but not obese.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. The Health Survey for England 2019 reported that 28% of adults in the UK were obese and 36.2% The drug was approved to treat type 2 diabetes mellitus in May. were overweight but not obese.

Medical 98

Medical Manufacturing Insurance Side effects 98